Cargando…
Genomic Testing for Relapsed and Refractory Lymphoid Cancers: Understanding Patient Values
BACKGROUND: New clinical genomic assays for lymphoid cancers allow for improved disease stratification and prognostication. At present, clinical implementation has been appropriately limited, owing to a paucity of evidence to support clinical and cost effectiveness. Understanding patients’ values fo...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884583/ https://www.ncbi.nlm.nih.gov/pubmed/32875479 http://dx.doi.org/10.1007/s40271-020-00448-1 |